^
Association details:
Biomarker:TIGIT underexpression
Cancer:Solid Tumor
Drug:TPST-1120 (PPAR α antagonist)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

2130 / 4 - Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha

Published date:
03/15/2023
Excerpt:
Patients with PR demonstrated significant elevations (p<0.05) in multiple genes including those associated with lipid transport (APOE), Th17 development (RORC) and down-regulation of CD155, a TIGIT ligand….TPST-1120 treated patients with PR demonstrated fatty acid oxidation perturbations and immune gene expression changes as potential biomarkers of clinical benefit.